510
Views
5
CrossRef citations to date
0
Altmetric
Review

Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond

&
Pages 669-686 | Received 23 Jan 2020, Accepted 13 Apr 2020, Published online: 27 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Alessandro Gozzetti, Sara Ciofini, Martina Simoncelli, Adele Santoni, Paola Pacelli, Donatella Raspadori & Monica Bocchia. (2022) Anti CD38 monoclonal antibodies for multiple myeloma treatment. Human Vaccines & Immunotherapeutics 18:5.
Read now

Articles from other publishers (4)

Fei-Fei Yang, Ting Hu, Jian-Quan Liu, Xiao-Qian Yu & Li-Ying Ma. (2023) Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment. European Journal of Medicinal Chemistry 245, pages 114920.
Crossref
Alessandro Gozzetti & Monica Bocchia. (2022) Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials. Reviews on Recent Clinical Trials 17:1, pages 9-10.
Crossref
Jeng-Shiun Du, Yi-Chun Kuo, Hon-Yi Shi, Ming-Chung Wang, Li-Ying Wang, Tzer-Ming Chuang, Ya-Lun Ke, Tsung-Jang Yeh, Yu-Ching Gau, Hui-Ching Wang, Shih-Feng Cho, Samuel Yien Hsiao, Yi-Chang Liu, Chin-Mu Hsu & Hui-Hua Hsiao. (2022) The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan. Journal of Personalized Medicine 12:2, pages 130.
Crossref
Juan José Lahuerta, Bruno Paiva, Ana Jiménez de Ubieto, José Sánchez-Pina, María-Victoria Mateos, Joan Bladé & Jesús F. San-Miguel. (2021) Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. Blood Advances 5:5, pages 1340-1343.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.